公开(公告)号：US20070148150A1

公开(公告)日：2007-06-28

申请号：US11705900

申请日：2007-02-14

申请人： Hirofumi Doi ,  Shinya Hosogi ,  Naoya Wada

发明人： Hirofumi Doi ,  Shinya Hosogi ,  Naoya Wada

IPC分类号： A61K38/54 ,  C12N9/99

CPC分类号： C07K14/47 ,  A61K38/1709 ,  G01N2500/00 ,  A61K2300/00

摘要： PAK4 and JIK, both of which bind to MKK7 and directly phosphorylate MKK7, were found in the present invention. The present invention provides an inhibitor of c-Jun phosphorylation caused by JNK3 and a method for inhibiting the same, and an agent for preventing and/or treating a disorder attributable to c-Jun phosphorylation caused by JNK3 and a method for preventing and/or treating the same, all of which comprise inhibiting one member selected from the following: the binding of PAK4 to MKK7, the phosphorylation of MKK7 by PAK4, the binding of JIK to MKK7, and the phosphorylation of MKK7 by JIK. Further, the present invention provides a method for identifying a compound that inhibits the binding of PAK4 to MKK7, the phosphorylation of MKK7 caused by PAK4, the binding of JIK to MKK7, or the phosphorylation of MKK7 caused by JIK, as well as the compound obtained thereby. Furthermore, the present invention provides a pharmaceutical composition containing an effective amount of at least one member selected from the group consisting of the aforementioned compound and the aforementioned inhibitor.

公开(公告)号：US20060172360A1

公开(公告)日：2006-08-03

申请号：US10519465

申请日：2003-06-27

申请人： Hirofumi Doi ,  Shinya Hosogi ,  Naoya Wada

发明人： Hirofumi Doi ,  Shinya Hosogi ,  Naoya Wada

IPC分类号： A61K38/54 ,  C12Q1/48

CPC分类号： C07K14/47 ,  A61K38/1709 ,  G01N2500/00 ,  A61K2300/00

摘要： PAK4 and JIK, both of which bind to MKK7 and directly phosphorylate MKK7, were found in the present invention. The present invention provides an inhibitor of c-Jun phosphorylation caused by JNK3 and a method for inhibiting the same, and an agent for preventing and/or treating a disorder attributable to c-Jun phosphorylation caused by JNK3 and a method for preventing and/or treating the same, all of which comprise inhibiting one member selected from the following: the binding of PAK4 to MKK7, the phosphorylation of MKK7 by PAK4, the binding of JIK to MKK7, and the phosphorylation of MKK7 by JIK. Further, the present invention provides a method for identifying a compound that inhibits the binding of PAK4 to MKK7, the phosphorylation of MKK7 caused by PAK4, the binding of JIK to MKK7, or the phosphorylation of MKK7 caused by JIK, as well as the compound obtained thereby. Furthermore, the present invention provides a pharmaceutical composition containing an effective amount of at least one member selected from the group consisting of the aforementioned compound and the aforementioned inhibitor.

摘要翻译： 在本发明中发现PAK4和JIK两者都结合MKK7并直接磷酸化MKK7。 本发明提供了由JNK3引起的c-Jun磷酸化抑制剂及其抑制方法，以及用于预防和/或治疗由JNK3引起的由c-Jun磷酸化引起的病症的药剂，以及用于预防和/或 所有这些都包括抑制选自以下的一种：PAK4与MKK7的结合，PAK4的MKK7的磷酸化，JIK与MKK7的结合以及通过JIK的MKK7的磷酸化。 此外，本发明提供了鉴定抑制PAK4与MKK7结合的化合物，由PAK4引起的MKK7的磷酸化，JIK与MKK7的结合或由JIK引起的MKK7的磷酸化的化合物的方法，以及化合物 由此获得。 此外，本发明提供含有有效量的选自上述化合物和上述抑制剂中的至少一种的药物组合物。

公开(公告)号：US07195894B2

公开(公告)日：2007-03-27

申请号：US10519465

申请日：2003-06-27

申请人： Hirofumi Doi ,  Shinya Hosogi ,  Naoya Wada

发明人： Hirofumi Doi ,  Shinya Hosogi ,  Naoya Wada

IPC分类号： C12N15/09

CPC分类号： C07K14/47 ,  A61K38/1709 ,  G01N2500/00 ,  A61K2300/00

摘要： PAK4 and JIK, both of which bind to MKK7 and directly phosphorylate MKK7, were found in the present invention. The present invention provides an inhibitor of c-Jun phosphorylation caused by JNK3 and a method for inhibiting the same, and an agent for preventing and/or treating a disorder attributable to c-Jun phosphorylation caused by JNK3 and a method for preventing and/or treating the same, all of which comprise inhibiting one member selected from the following: the binding of PAK4 to MKK7, the phosphorylation of MKK7 by PAK4, the binding of JIK to MKK7, and the phosphorylation of MKK7 by JIK. Further, the present invention provides a method for identifying a compound that inhibits the binding of PAK4 to MKK7, the phosphorylation of MKK7 caused by PAK4, the binding of JIK to MKK7, or the phosphorylation of MKK7 caused by JIK, as well as the compound obtained thereby. Furthermore, the present invention provides a pharmaceutical composition containing an effective amount of at least one member selected from the group consisting of the aforementioned compound and the aforementioned inhibitor.

摘要翻译： 在本发明中发现PAK4和JIK两者都结合MKK7并直接磷酸化MKK7。 本发明提供了由JNK3引起的c-Jun磷酸化抑制剂及其抑制方法，以及用于预防和/或治疗由JNK3引起的由c-Jun磷酸化引起的病症的药剂，以及用于预防和/或 所有这些都包括抑制选自以下的一种：PAK4与MKK7的结合，PAK4的MKK7的磷酸化，JIK与MKK7的结合以及通过JIK的MKK7的磷酸化。 此外，本发明提供了鉴定抑制PAK4与MKK7结合的化合物，由PAK4引起的MKK7的磷酸化，JIK与MKK7的结合或由JIK引起的MKK7的磷酸化的化合物的方法，以及化合物 由此获得。 此外，本发明提供含有有效量的选自上述化合物和上述抑制剂中的至少一种的药物组合物。

公开(公告)号：US20050037449A1

公开(公告)日：2005-02-17

申请号：US10901923

申请日：2004-07-29

申请人： Hirofumi Doi ,  Naoya Wada

发明人： Hirofumi Doi ,  Naoya Wada

IPC分类号： A61K38/00 ,  A61K39/00 ,  A61K45/00 ,  A61P25/00 ,  C12Q1/48 ,  G01N33/68 ,  C12Q1/68 ,  A61K31/66

CPC分类号： G01N33/6893 ,  C12Q1/485 ,  G01N2500/02

摘要： A method for controlling circadian rhythm disorders is described, characterized by inhibiting the phosphorylation of BMAL1 by c-Jun N-terminal kinase 3 (JNK3) due to the interaction between JNK3 and BMAL1; a method for preventing and/or treating diseases caused by circadian rhythm disorders; and a method for identifying a compound that inhibit phosphorylation of BMAL1 by JNK3. Also provided are: an agent for controlling circadian rhythm disorders, having the above characteristics; an agent for treating and/or preventing diseases caused by circadian rhythm disorders; a compound obtained by the identification method described above; an agent for inhibiting the phosphorylation of BMAL1 by JNK3, containing the compound; an agent for recovering the suppressed transcriptional activity of the complexes containing BMAL1 and CLOCK and for inhibiting the phosphorylation the same, containing an agent for inhibiting the expression and/or function of JNK3; and a pharmaceutical composition containing one of these.

摘要翻译： 描述了一种控制昼夜节律紊乱的方法，其特征在于由于JNK3与BMAL1之间的相互作用，通过c-Jun N-末端激酶3（JNK3）抑制BMAL1的磷酸化; 用于预防和/或治疗由昼夜节律紊乱引起的疾病的方法; 以及通过JNK3鉴定抑制BMAL1磷酸化的化合物的方法。 还提供：具有上述特征的用于控制昼夜节律紊乱的药剂; 用于治疗和/或预防由昼夜节律紊乱引起的疾病的药剂; 通过上述鉴定方法获得的化合物; 用于抑制含有该化合物的JNK3的BMAL1磷酸化的试剂; 用于回收含有BMAL1和CLOCK的复合物的抑制转录活性并抑制其磷酸化的试剂，其含有抑制JNK3的表达和/或功能的试剂; 和含有这些之一的药物组合物。

公开(公告)号：US20060276387A1

公开(公告)日：2006-12-07

申请号：US10544061

申请日：2004-11-26

申请人： Hirofumi Doi ,  Kensaku Imai ,  Naoya Wada

发明人： Hirofumi Doi ,  Kensaku Imai ,  Naoya Wada

IPC分类号： A61K38/22 ,  C12Q1/68 ,  G01N33/53

CPC分类号： C07K14/62 ,  G01N33/74 ,  G01N2500/02

摘要： A method for promoting insulin gene transcription, which comprises the step of inhibiting binding of IPF1 and any one of proteins selected from the following group: (i) HNF3G, (ii) PHF1, and (iii) DLX4; and a method for screening a substance that promotes insulin gene transcription, which comprises the step of bringing a test substance into contact with IPF1 and/or any one of proteins selected from the following group under a condition that allows the binding of IPF1 and said protein and then determining whether or not the test substance inhibits the binding of IPF1 and said protein by detecting presence or absence, or change of a signal and/or a marker generated by the binding of IPF1 and said protein in a system in which the signal and/or the marker can be detected: (i) HNF3G, (ii) PHF1, and (iii) DLX4.

摘要翻译： 一种促进胰岛素基因转录的方法，其包括抑制IPF1与选自以下组中的任何一种蛋白质结合的步骤：（i）HNF3G，（ii）PHF1和（iii）DLX4; 以及用于筛选促进胰岛素基因转录的物质的方法，其包括在允许IPF1和所述蛋白质结合的条件下使测试物质与IPF1和/或选自以下组的任何一种蛋白质接触的步骤 然后通过检测存在或不存在检测物质来抑制IPF1和所述蛋白质的结合，或者通过IPF1和所述蛋白质的结合产生的信号和/或标记的变化来抑制IPF1和所述蛋白质的结合，其中信号和 /或可以检测标记：（i）HNF3G，（ii）PHF1和（iii）DLX4。

公开(公告)号：US20070105796A1

公开(公告)日：2007-05-10

申请号：US10563074

申请日：2005-04-28

申请人： Naoya Wada ,  Takashi Okamoto ,  Keiji Tanigaki ,  Hirofumi Doi ,  Yasuhiro Kikuchi ,  Kensaku Imai

发明人： Naoya Wada ,  Takashi Okamoto ,  Keiji Tanigaki ,  Hirofumi Doi ,  Yasuhiro Kikuchi ,  Kensaku Imai

IPC分类号： A61K48/00

CPC分类号： C12N9/1205

摘要： The present invention provides a method for inhibiting the activation of telomerase and an agent for inhibiting the activation of telomerase, a method for inhibiting telomerase activity and an agent for inhibiting telomerase activity, a method for preventing and/or a method for treating a cancer disease, an agent for preventing and/or an agent for treating a cancer disease, all of which comprises inhibiting the binding of MAPKAPK3 to TERT that is a catalytic subunit of telomerase or inhibiting the phosphorylation of TERT by active MAPKAPK3; a method of identifying a compound that inhibits the binding of MAPKAPK3 to TERT or a compound that inhibits the phosphorylation of TERT by active MAPKAPK3; and a reagent kit.

摘要翻译： 本发明提供抑制端粒酶活化的方法和抑制端粒酶活化的试剂，抑制端粒酶活性的方法和抑制端粒酶活性的方法，预防和/或治疗癌症的方法 ，用于预防和/或治疗癌症疾病的药物，所有这些都包括抑制MAPKAPK3与作为端粒酶催化亚基的TERT的结合或抑制活性MAPKAPK3的TERT磷酸化; 鉴定抑制MAPKAPK3与TERT结合的化合物或抑制活性MAPKAPK3磷酸化TERT的化合物的方法; 和试剂盒。

公开(公告)号：US20080004355A1

公开(公告)日：2008-01-03

申请号：US11793959

申请日：2005-12-27

申请人： Naoya Wada ,  Takashi Okamoto ,  Keiji Tanigaki ,  Hirofumi Doi ,  Kensaku Imai

发明人： Naoya Wada ,  Takashi Okamoto ,  Keiji Tanigaki ,  Hirofumi Doi ,  Kensaku Imai

IPC分类号： A61K35/00 ,  A61P35/00 ,  C12N15/63 ,  C12N5/00 ,  C12N9/10 ,  C12Q1/34 ,  C12Q1/48 ,  C12Q1/68

CPC分类号： C12Y207/07049 ,  A61K45/06 ,  C12N9/1241 ,  G01N33/574 ,  G01N2333/9125 ,  G01N2333/916 ,  G01N2500/02

摘要： A method is described for enhancing degradation of telomerase. This method includes inhibiting the binding of TERT (telomerase catalytic subunit) to USP21, the binding of NEDD8-conjugated TERT to USP21, or the NEDD8 deconjugation by USP21 from NEDD8-conjugated TERT. A method of inhibiting telomerase activity is also described. The method includes utilizing the method of enhancing the degradation. A method of identifying a compound that inhibits the binding or the NEDD8 deconjugation is further described. An agent for inhibiting telomerase activity is described. An agent for preventing and/or treating diseases attributable to the enhanced telomerase activity is described and includes an inhibitory agent. Also, a method of preventing and/or treating diseases is described and includes using the inhibition method or the inhibitory agent. Further, a reagent kit is described.

摘要翻译： 描述了一种增强端粒酶降解的方法。 该方法包括抑制TERT（端粒酶催化亚单位）与USP21的结合，NEDD8缀合的TERT与USP21的结合，或者通过NEDD8缀合的TERT的USP21的NEDD8解缀。 还描述了抑制端粒酶活性的方法。 该方法包括利用增强降解的方法。 进一步描述鉴定抑制结合或NEDD8解缀合的化合物的方法。 描述了抑制端粒酶活性的药剂。 描述了用于预防和/或治疗归因于增强的端粒酶活性的疾病的药剂，并且包括抑制剂。 此外，描述了预防和/或治疗疾病的方法，并且包括使用抑制方法或抑制剂。 此外，描述了试剂盒。

公开(公告)号：US20050065082A1

公开(公告)日：2005-03-24

申请号：US10509307

申请日：2003-03-31

申请人： Hirofumi Doi ,  Naoya Wada ,  Hiroto Nakajima

发明人： Hirofumi Doi ,  Naoya Wada ,  Hiroto Nakajima

IPC分类号： A61K38/17 ,  A61P25/00 ,  A61K38/52 ,  C12N9/99

CPC分类号： A61K38/1709

摘要： In the present invention, BMAL1, BPL1, KIAA1491 complete (SEQ ID NO: 1), and KIAA0596CT (SEQ ID NO:2), have a function for interacting with JNK3, wherein these peptides, as well as peptides derived therefrom can be used to inhibit c-Jun from being phosphorylated and exhibiting its functions (such as transcription activation activity). Inhibition of the phosphorylation of c-Jun suppresses apoptosis, such as nerve cell apoptosis. Thus, the present invention also provides a drug, a pharmaceutical composition and a method for use in preventing and/or treating a neurodegenerative disease (such as polyglutamine disease and Alzheimer's disease).

摘要翻译： 在本发明中，BMAL1，BPL1，KIAA1491完整（SEQ ID NO：1）和KIAA0596CT（SEQ ID NO：2）具有与JNK3相互作用的功能，其中可以使用这些肽以及由其衍生的肽 以抑制c-Jun被磷酸化并显示其功能（例如转录激活活性）。 抑制c-Jun磷酸化抑制细胞凋亡，如神经细胞凋亡。 因此，本发明还提供了用于预防和/或治疗神经退行性疾病（如聚谷氨酰胺病和阿尔茨海默病）的药物，药物组合物和方法。

公开(公告)号：US08982442B2

公开(公告)日：2015-03-17

申请号：US14126161

申请日：2012-06-12

申请人： Naoya Wada ,  Seitetsu Boku ,  Hiroyuki Yamazaki ,  Yusaku Tottori

发明人： Naoya Wada ,  Seitetsu Boku ,  Hiroyuki Yamazaki ,  Yusaku Tottori

IPC分类号： G02F1/01 ,  G02B27/00

CPC分类号： G02F1/0136 ,  G02B27/00 ,  G02B27/286 ,  G02F2203/58 ,  G02F2203/585

摘要： A wavelength selective polarization controller capable of controlling the polarization plane of optical wavelength multiplexing signals, for each wavelength component, and which does not generate time lag between each component is provided. This wavelength selective polarization controller has: a telecentric optical system to which optical wavelength multiplexing signals are incident; a polarization controller that controls the polarization plane of light output from the telecentric optical system; and an output optical system for outputting to an optical path output from the polarization controller. The telecentric optical system has: a first diffraction grating to which the optical wavelength multiplexing signals are incident; and a first condenser that condenses the optical wavelength multiplexing signals that have passed through the diffraction grating. The polarization controller has a plurality of phase modulators.

摘要翻译： 提供一种波长选择性偏振控制器，其能够对于每个波长分量控制光波分复用信号的偏振面，并且不会在每个分量之间产生时滞。 该波长选择性偏振控制器具有：光波长复用信号入射的远心光学系统; 偏振控制器，其控制从远心光学系统输出的光的偏振面; 以及用于输出到从偏振控制器输出的光路的输出光学系统。 远心光学系统具有：光波长复用信号入射的第一衍射光栅; 以及冷凝已经通过衍射光栅的光波长复用信号的第一电容器。 偏振控制器具有多个相位调制器。

公开(公告)号：US08575834B2

公开(公告)日：2013-11-05

申请号：US13447014

申请日：2012-04-13

申请人： Naoya Wada ,  Nobuhiro Nakamura

发明人： Naoya Wada ,  Nobuhiro Nakamura

IPC分类号： H01L51/52

CPC分类号： H01L51/5268 ,  C03C3/066 ,  C03C3/068 ,  C03C3/14 ,  C03C3/16 ,  C03C3/19 ,  C03C3/21 ,  C03C8/04 ,  C03C8/08 ,  C03C17/007 ,  G02B5/0278

摘要： The present invention relates to a glass for a scattering layer of an organic LED element, which contains, in terms of mol % on the basis of oxides, 0˜20% of P2O5, 15˜60% of B2O3, 15˜28% of Bi2O3 and 20˜50% of ZnO, in which a value obtained by dividing the content of P2O5 by the content of ZnO is less than 0.48, the sum of the contents of P2O5 and B2O3 is 30˜60%, the content of P2O5 is 10% or less when the sum of the contents of P2O5 and B2O3 exceeds 50%, and the glass does not substantially contain lead (PbO or Pb3O4), Li2O, Na2O and K2O, except for those contained as impurities.

摘要翻译： 本发明涉及一种有机LED元件的散射层用玻璃，其含有以氧化物为基准的摩尔％，0〜20％的P 2 O 5，15〜60％的B 2 O 3，15〜28％的 Bi2O3和20〜50％的ZnO，其中通过将P2O5的含量除以ZnO的含量获得的值小于0.48，P2O5和B2O3的含量之和为30〜60％，P2O5的含量为 当P 2 O 5和B 2 O 3的含量的总和超过50％时，10％以下，除了作为杂质以外，玻璃基本上不含有铅（PbO或Pb 3 O 4），Li 2 O，Na 2 O，K 2 O。